|
News for: |
|
You will land on a page at the National Library of Medicine where you can drill down to consumer info, research citations, product labelling, toxicology and more. FindingHealthOnline is the world's leading health-pharma search portal and decision engine. It helps you drill down to very detailed information without interference from commercial sites that now dominate Bing, Google, and Yahoo. Near the top of our pages, you will find a link to content that best matches your query.
|
|
|
FDA Approval Activities for this Drug…
Relenza (zanamivir for inhalation), GlaxoSmithKline 21-036/S006 8/6/03 8/15/03 8/15/03 Relenza (zanamivir for inhalation), GlaxoSmithKline 21-036/S005 8/5/03 8/15/03 8/6/03 Relenza (zanamivir for inhalation), 5 mg, Glaxo Wellcome, 21-036/S004 4/27/01 05/08/03 Relenza (zanamivir for inhalation),5 mg, Patient Label Glaxo Wellcome, 21-036/S001 4/26/00 4/27/00 4/27/00 Relenza (zanamivir for inhalation) GlaxoWellcome NDA 21-036 7/26/99 12/30/99 7/27/99 12/27/99 Relenza Indication: For the treatment of uncomplicated acute illness due to influenza virus in adults and adolescents twelve years and older who have been symptomatic for no more than two days. | RELENZA (zanamivir) inhalation, GlaxoSmithKline, New or Modified Indication | RELENZA (zanamivir) Inhalation, GlaxoSmithKline, Labeling Revision
|